Van Herk Investments notify of 5.3% shareholding in Galapagos
January 06 2014 - 12:04PM
Galapagos NV (Euronext:GLPG)
received
notice that Van Herk Investments currently holds 5.3% of
outstanding Galapagos shares.
Pursuant to Belgian transparency legislation[1],
Galapagos received notice on 31 December 2013 from Van Herk
Investments B.V., stating that they held 1,586,727 shares.
This represents 5.3% of the 29,794,046 Galapagos shares currently
outstanding and marks the first transparency notice that Galapagos
has received from Van Herk Investments.
About Van Herk Investments
Part of the Van Herk Group of companies, Van Herk Investments is
invested in listed and private companies. Van Herk
Investments has a global orientation, with holdings in
construction, project development, biotechnology and life sciences,
financial services, and energy sectors. Current biotechnology
and life sciences holdings include Agendia, ART, BioInvent,
CardioGenX, Galapagos, Nightbalance, SkylineDx and VitalNext.
More information at www.vanherkgroep.nl
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising of six Phase 2
studies (three led by GSK), one Phase 1 study, five pre-clinical,
and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications.
AbbVie and Galapagos signed an agreement in CF where they work
collaboratively to develop and commercialize oral drugs that
address two mutations in the CFTR gene, the G551D and F508del
mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1
inhibitor in Phase 2 in ulcerative colitis, psoriasis, and lupus,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is
currently in a Proof-of-Concept Phase 2 study. GLPG1205 is a
first-in-class molecule that targets inflammatory disorders and has
completed Phase 1 studies.
The Galapagos Group, including fee-for-service companies
BioFocus, Argenta and Fidelta, has around 800 employees and
operates facilities in five countries, with global headquarters in
Mechelen, Belgium. Further information, including an updated
major shareholder overview, can be found at: www.glpg.com
Contact
Galapagos NV Elizabeth Goodwin, Director
Investor Relations Tel: +31 6 2291 6240 ir@glpg.com
Galapagos forward-looking statements This
release may contain forward-looking statements, including, without
limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation. [1]
Belgian Act of 2 May 2007 on the disclosure of major shareholdings
in issuers whose shares are admitted to trading on a regulated
market.
Van Herk Investments notify of 5.3% shareholding in Galapagos
http://hugin.info/133350/R/1752896/591125.pdf
HUG#1752896
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jul 2023 to Jul 2024